Scarica l'app Stockscreener
23.17
0.12%
0.1995
Uniqure Nv Borsa (QURE) Ultime notizie
Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - statnews.com
$uniQure NV (QURE.US)$ - Moomoo
uniQure N.V. (QURE) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.
UniQure Price Target Cut to $31.00/Share From $46.00 by Goldman Sachs - Moomoo
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha
uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance
Is uniQure (NASDAQ:QURE) Rewriting the Healthcare Stocks Playbook Today? - Kalkine Media
H.C. Wainwright reiterates uniQure stock rating citing trial data By Investing.com - Investing.com Nigeria
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha
Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView
UNIQURE N.V.MEAN CSF NFL 6% BELOW BASELINE AT 36 MONTHS FOR 14 HIGH-DOSE PATIENTS - webull.com
Why uniQure shares are sinking after AMT-130 update - The Economic Times
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar
Top Midday Decliners - Moomoo
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit - Yahoo Finance
UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble - marketscreener.com
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE) - Seeking Alpha
uniQure N.V. stock Analysis: 37% Crash Highlights Oversold Risks - The Cryptonomist
uniQure Sheds Nearly Half Its Value as 48-Month Huntington's Data Disappoints - finance.biggo.com
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression SlowingSlideshow (NASDAQ:QURE) 2026-09-29 - Seeking Alpha
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law - Business Wire
uniQure reports 48-month data for Huntington’s disease therapy By Investing.com - Investing.com Nigeria
Pattern recognition? Uniqure dips on new HD results - BioWorld News
uniQure tanks is it reports new data from Phase I/II studies of ifezuntirgene inilparvovec - The Pharma Letter
Why is uniQure stock collapsing today? By Investing.com - Investing.com Australia
QURE Investor Alert: uniQure Securities InvestigationKehoe Law Firm, P.C. - True North Radio Network
Why Is uniQure Stock Sinking on Tuesday? - Yahoo Finance
Form 8K uniQure N.V. For: 29 September By Investing.com - Investing.com South Africa
Stifel reiterates uniQure stock rating on Huntington’s data By Investing.com - Investing.com Nigeria
uniQure Highlights Long-Term AMT-130 Huntington’s Data - TipRanks
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - Yahoo Finance
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - Yahoo Finance
uniQure: AMT-130 phase I/II data show sustained functional benefit at 36–48 months - TradingView
uniQure: 80% Slowing on Huntington's Score at 3 Years - Stock Titan
uniQure (QURE) Shares Plunge Over 50% Premarket After Mixed AMT-130 Huntington's Data - GuruFocus
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - Yahoo Finance
ClearPoint Neuro stock tumbles on uniQure trial setback - Investing.com
UniQure plunges as Huntington's trial data disappoints investors - marketscreener.com
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - Yahoo Finance
uniQure posts new data for Huntington’s disease drug (QURE) - Seeking Alpha
QURE Stock Whipsaws As Traders Weigh Cash Pile Against Heavy Losses - StocksToTrade
Why is uniQure stock collapsing today? - Investing.com
uniQure Announces Additional Data from Ongoing Phase I/II - GlobeNewswire
UniQure’s gene therapy continues to slow Huntington’s progression after four years - statnews.com
UniQure Sinks After Worse-Than-Expected Huntington’s Results - Bloomberg.com
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
QURE Stock Price, Quote & Chart - ChartMill
uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS
Why is uniQure stock sliding today? - Investing.com
Why is uniQure stock sliding today? By Investing.com - Investing.com Australia
uniQure stock falls 5.57 percent as cash reaches USD 810.3 million - AD HOC NEWS
uniQure stock eyes key AMT-130 update as Huntington’s gene therapy advances - ad-hoc-news.de
uniQure stock holds recent gains as Huntington’s gene therapy filing reshapes outlook - AD HOC NEWS
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Eastern Progress
What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT
0.33%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):